Beyond breast cancer, ERBB2 amplification and HER2 overexpression are observed across other various tumor types such as gastric, bladder, colorectal, bile duct, and non-small cell lung cancers (2, 6). This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.